Overview

Pilot Study Reduced Fluence PDT /Visudyne With Ranibizumab vs Ranibizumab Monotherapy for Exudative Age-related Macular Degeneration (AMD)

Status:
Withdrawn

Trial end date:
2012-07-01

Target enrollment:

Participant gender:

Summary

The purposes of this study is to determine if combination reduced fluence photodynamic therapy and Ranibizumab has: Similar efficacy to Ranibizumab (Lucentis) alone. The ability to reduce the number of intravitreal injection of Ranibizumab or a 13 month period The ability to reduce the number of PDT treatments. The study will also collect information on the safety of combination therapy and single therapy.

Phase:

N/A

Details

Lead Sponsor:

Lahey Clinic

Treatments:

Ranibizumab
Verteporfin